Anti-tumor necrosis factor-a treatment with infliximab for disseminated granuloma annulare

Giuseppe Murdaca, Barbara Maria Colombo, Gianfranco Barabino, Matteo Caiti, Paola Cagnati, Francesco Puppo

Research output: Contribution to journalArticlepeer-review

Abstract

Granuloma annulare (GA) is a chronic inflammatory disease of unknown etiology characterized by the development of plaques preferentially localized to the distal extremities. Spontaneous remission and relapses are quite common and the course of GA is not easy to predict. Moreover, most therapeutic regimens have been used anecdotally and with variable success. We report the case of a 62-year-old White female patient affected by disseminated GA unsuccessfully treated with psoralen plus UVA photochemotherapy, prednisone, and cyclosporine (ciclosporin) who responded to the anti-tumor necrosis factor-a monoclonal antibody infliximab administered intravenously at a dosage of 5mg/kg at weeks 0, 2, and 6 and thereafter at monthly intervals for 10 additional months. Most of the GA lesions improved within 8 weeks and then slowly resolved within 10 months of treatment. We suggest that infliximab may be proposed as an additional therapeutic option in the treatment of recalcitrant forms of disseminated GA.

Original languageEnglish
Pages (from-to)437-439
Number of pages3
JournalAmerican Journal of Clinical Dermatology
Volume11
Issue number6
DOIs
Publication statusPublished - 2010

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Anti-tumor necrosis factor-a treatment with infliximab for disseminated granuloma annulare'. Together they form a unique fingerprint.

Cite this